A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants - Trial 2022-002191-36
Access comprehensive clinical trial information for 2022-002191-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Shire and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2022-002191-36
Trial Details
EU Clinical Trials Register • 2022-002191-36
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
Study Focus
Sponsor & Location
Shire
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- Part 1: Maximum Concentration (Cmax) Occurred at Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Maribavir in Plasma
ICD-10 Classifications
Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams
Routine general health check-up of inhabitants of institutions
Data Source
EU Clinical Trials Register
2022-002191-36
Non-Device Trial